J&J Gets Phase II Win for First Targeted Oral Peptide in Plaque Psoriasis

Johnson & Johnson on Saturday unveiled long-term data from its Phase IIb FRONTIER 2 trial, demonstrating that its investigational peptide therapeutic JNJ-2113 could maintain high rates of skin clearance through one year in patients with moderate-to-severe plaque psoriasis.